Literature DB >> 1854453

In vitro pharmacology of DuP 753.

A T Chiu1, D E McCall, W A Price, P C Wong, D J Carini, J V Duncia, R R Wexler, S E Yoo, A L Johnson, P B Timmermans.   

Abstract

DuP 753, 2-n-butyl-4-chloro-5-hydroxymethyl-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl)methyl]imidazole, potassium salt, was characterized in vitro with respect to its affinity and specificity for functional antagonism of angiotensin II (AII) receptors. In rat adrenal cortical microsomes and cultured aortic smooth muscle cells DuP 753 inhibited the specific binding of [125I]AII in a concentration-dependent manner yielding IC50 values of 1.7 and 2.0 x 10(-8) mol/L, respectively. In contrast, DuP 753 had no appreciable affinity for other receptor systems as well as for Ca2+ channels. Functional antagonism was demonstrated by its blockade of AII-induced 45Ca2+ efflux in rat smooth muscle cells. The AII-induced contraction of rabbit aortic strips was competitively antagonized by DuP 753 resulting in a pA2 value of 8.48. Responses induced by other agonists, such as norepinephrine and KCl, were not altered. No partial agonistic effect was noted in any of the in vitro assays. In addition, DuP 753 (10(-5) mol/L) had no effect on rabbit lung converting enzyme or rat/human renin activity. These data demonstrate that DuP 753 is a highly potent and specific AII receptor antagonist. DuP 753 represents a useful experimental tool for dissecting the role of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854453     DOI: 10.1093/ajh/4.4.282s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

Review 1.  Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?

Authors:  F D Hobbs
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

Review 2.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

3.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.

Authors:  L Criscione; M de Gasparo; P Bühlmayer; S Whitebread; H P Ramjoué; J Wood
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

5.  Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.

Authors:  P Müller; T Cohen; M de Gasparo; A Sioufi; A Racine-Poon; H Howald
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.